|
US5538983A
(en)
|
1990-05-16 |
1996-07-23 |
The Rockefeller University |
Method of treating amyloidosis by modulation of calcium
|
|
CA2113115A1
(en)
|
1991-07-29 |
1993-02-18 |
Vlad E. Gregor |
Quinazoline derivatives as acetylcholinesterase inhibitors
|
|
IT1255179B
(it)
|
1992-06-26 |
1995-10-20 |
Enzo Cereda |
Azaciclo e azabiciclo alchiliden idrossilamine
|
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
|
JP2992677B2
(ja)
|
1995-06-05 |
1999-12-20 |
武田薬品工業株式会社 |
骨形成促進医薬組成物
|
|
AU5716898A
(en)
|
1997-01-08 |
1998-08-03 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
|
WO1999036384A1
(en)
|
1998-01-16 |
1999-07-22 |
Purdue Research Foundation |
Alkenyldiarylmethane non-nucleoside hiv-1 reverse transcriptase inhibitors
|
|
DE69934093T2
(de)
|
1998-01-27 |
2007-06-21 |
Aventis Pharmaceuticals Inc. |
SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
|
|
JP2003529531A
(ja)
|
1998-11-25 |
2003-10-07 |
アヴェンティス ファーマシューティカルズ インコーポレイテッド |
置換オキソアザへテロシクリルＸａ因子阻害剤
|
|
CA2382755A1
(en)
|
1999-07-28 |
2001-02-01 |
Aventis Pharmaceuticals Products Inc. |
Substituted oxoazaheterocyclyl compounds
|
|
JP2001131173A
(ja)
|
1999-08-23 |
2001-05-15 |
Kyorin Pharmaceut Co Ltd |
二環式複素環誘導体
|
|
JP2005231995A
(ja)
|
1999-12-22 |
2005-09-02 |
Meiji Seika Kaisha Ltd |
オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
WO2002003684A2
(en)
|
2000-06-30 |
2002-01-10 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
|
EP1372620A2
(en)
|
2001-03-15 |
2004-01-02 |
Saegis Pharmaceuticals |
Methods for restoring cognitive function following systemic stress
|
|
US20040023951A1
(en)
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
|
US20030004913A1
(en)
|
2001-07-02 |
2003-01-02 |
Koninklijke Philips Electronics N.V. |
Vision-based method and apparatus for detecting an event requiring assistance or documentation
|
|
PL371722A1
(en)
|
2001-11-26 |
2005-06-27 |
Cortex Pharmaceuticals, Inc. |
Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
|
|
US20040044023A1
(en)
|
2002-08-30 |
2004-03-04 |
Marc Cantillon |
Compositions and methods for treating or preventing memory impairment
|
|
EP1596867A4
(en)
|
2003-02-19 |
2006-03-22 |
Merck & Co Inc |
TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
|
|
JP2006521399A
(ja)
|
2003-03-28 |
2006-09-21 |
アカディア ファーマシューティカルズ，インコーポレーテッド |
疼痛管理用ムスカリンｍ１受容体アゴニスト
|
|
US20040266659A1
(en)
|
2003-06-27 |
2004-12-30 |
Stephen LaBerge |
Substances that enhance recall and lucidity during dreaming
|
|
GB0504019D0
(en)
|
2005-02-26 |
2005-04-06 |
Astrazeneca Ab |
Amide derivatives
|
|
US20090156581A1
(en)
|
2005-04-15 |
2009-06-18 |
Board Of Trustrees Of Michigan State University |
Aminergic pharmaceutical compositions and methods
|
|
GB0516570D0
(en)
|
2005-08-12 |
2005-09-21 |
Astrazeneca Ab |
Amide derivatives
|
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス，インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
|
WO2007044937A2
(en)
|
2005-10-13 |
2007-04-19 |
President And Fellows Of Harvard College |
Compositions and methods to modulate memory
|
|
HUE030390T2
(en)
|
2005-12-21 |
2017-05-29 |
Janssen Pharmaceutica Nv |
Triazolopyridazines as tyrosine kinase modulators
|
|
GB0607946D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607949D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607952D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res Ltd |
Novel treatment
|
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US7834023B2
(en)
|
2006-09-20 |
2010-11-16 |
Portola Pharmaceuticals, Inc. |
Substituted dihydroquinazolines as platelet ADP receptor inhibitors
|
|
MY154877A
(en)
*
|
2007-01-03 |
2015-08-14 |
Servier Lab |
3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamateric synaptic responses
|
|
US8618074B2
(en)
|
2007-03-15 |
2013-12-31 |
Board Of Regents Of The University Of Texas System |
GPCR enhanced neuroprotection to treat brain injury
|
|
CA2697500A1
(en)
|
2007-08-29 |
2009-03-12 |
Schering Corporation |
2,3-substituted azaindole derivatives for treating viral infections
|
|
ES2447543T3
(es)
|
2007-08-29 |
2014-03-12 |
Merck Sharp & Dohme Corp. |
Derivados de indol sustituidos y métodos de utilización de los mismos
|
|
EP2197842B1
(en)
|
2007-08-29 |
2012-05-23 |
Schering Corporation |
2, 3-substituted indole derivatives for treating viral infections
|
|
WO2009039461A2
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
JP2010540454A
(ja)
|
2007-09-21 |
2010-12-24 |
アカディア ファーマシューティカルズ，インコーポレーテッド |
ピマバンセリンと他の薬剤との併用投与
|
|
EP2222672B1
(en)
|
2007-11-16 |
2013-12-18 |
Merck Sharp & Dohme Corp. |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
|
CA2705586A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
|
US20110024198A1
(en)
|
2008-02-19 |
2011-02-03 |
Baker Hughes Incorporated |
Bearing systems containing diamond enhanced materials and downhole applications for same
|
|
WO2010042603A1
(en)
|
2008-10-08 |
2010-04-15 |
Cingulate Neuro Therapeutics, Llc |
Amyloid and depression
|
|
US8557832B2
(en)
*
|
2008-11-20 |
2013-10-15 |
Merck Sharp & Dohme Corp. |
Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators
|
|
EP2398324B1
(en)
|
2009-02-23 |
2014-09-03 |
Merck Sharp & Dohme Corp. |
PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
|
|
WO2010102218A1
(en)
|
2009-03-05 |
2010-09-10 |
Mithridion, Inc. |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
US8293744B2
(en)
|
2009-04-20 |
2012-10-23 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
|
|
ES2353093B1
(es)
|
2009-05-20 |
2012-01-03 |
Consejo Superior De Investigaciones Científicas (Csic) |
Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
|
|
US10265311B2
(en)
|
2009-07-22 |
2019-04-23 |
PureTech Health LLC |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
EP3061821B1
(en)
|
2009-07-22 |
2019-07-10 |
Puretech Health LLC |
Compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
KR101651312B1
(ko)
*
|
2009-08-31 |
2016-08-25 |
머크 샤프 앤드 돔 코포레이션 |
피라닐 아릴 메틸 벤조퀴나졸리논 ｍ1 수용체 양성 알로스테릭 조절제
|
|
EP2490692B1
(en)
|
2009-10-21 |
2016-11-16 |
Merck Sharp & Dohme Corp. |
Quinolinone-pyrazolone m1 receptor positive allosteric modulators
|
|
US8664387B2
(en)
|
2009-12-14 |
2014-03-04 |
Merck Sharp & Dohme Corp. |
Pyridoquinazolinone M1 receptor positive allosteric modulators
|
|
EP2515656B1
(en)
|
2009-12-21 |
2014-08-06 |
Merck Sharp & Dohme Corp. |
Aminobenzoquinazolinone m1 receptor positive allosteric modulators
|
|
US8557992B2
(en)
|
2010-06-15 |
2013-10-15 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
|
|
WO2012003147A1
(en)
|
2010-07-01 |
2012-01-05 |
Merck Sharp & Dohme Corp. |
Isoindolone m1 receptor positive allosteric modulators
|
|
WO2012047702A1
(en)
*
|
2010-10-04 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
|
|
WO2012149524A1
(en)
|
2011-04-29 |
2012-11-01 |
The University Of Toledo |
Muscarinic agonists as enhancers of working memory and cognitive flexibility
|
|
EP2709624B1
(en)
*
|
2011-05-17 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
|
|
WO2012170599A1
(en)
|
2011-06-10 |
2012-12-13 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2821401B1
(en)
|
2012-03-02 |
2020-09-09 |
Takeda Pharmaceutical Company Limited |
Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor
|
|
US9914722B2
(en)
|
2012-03-23 |
2018-03-13 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
US20130289019A1
(en)
|
2012-04-26 |
2013-10-31 |
Amazing Grace, Inc. |
Methods of treating behaviorial and/or mental disorders
|
|
EP2921480B1
(en)
|
2012-11-19 |
2017-10-11 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
JP6075408B2
(ja)
|
2012-11-22 |
2017-02-08 |
株式会社デンソー |
物標検出装置
|
|
CA2886139A1
(en)
|
2012-12-27 |
2014-07-03 |
F. Hoffmann-La Roche Ag |
Comt inhibitors
|
|
CA2899957A1
(en)
|
2013-02-04 |
2014-08-07 |
Merck Patent Gmbh |
Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
|
|
AU2014262862B2
(en)
|
2013-05-06 |
2018-08-30 |
Gachon University Of Industry-Academic Cooperation Foundation |
Compounds for treatment of angiogenesis-mediated diseases
|
|
JP6063400B2
(ja)
|
2014-01-08 |
2017-01-18 |
株式会社日立ビルシステム |
エレベータの異常監視装置
|
|
TWI664165B
(zh)
|
2014-04-23 |
2019-07-01 |
日商武田藥品工業股份有限公司 |
含氮雜環化合物
|
|
EP3144308B1
(en)
|
2014-05-16 |
2020-06-24 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
JP6571077B2
(ja)
|
2014-06-13 |
2019-09-04 |
武田薬品工業株式会社 |
含窒素複素環化合物
|
|
KR20180019234A
(ko)
*
|
2015-06-26 |
2018-02-23 |
다케다 야쿠힌 고교 가부시키가이샤 |
콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
|
|
WO2017044693A1
(en)
|
2015-09-11 |
2017-03-16 |
Chase Pharmaceuticals Corporation |
Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
|
|
JP6787913B2
(ja)
|
2015-10-20 |
2020-11-18 |
武田薬品工業株式会社 |
複素環化合物
|
|
EP3428150B1
(en)
|
2016-03-11 |
2023-07-12 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity
|
|
WO2018122845A1
(en)
|
2016-12-29 |
2018-07-05 |
Rvx Therapeutics Ltd. |
Methods and compositions for potentiating cns drugs and reducing their side effects
|